Navigation Links
Active Biotech presents new pre-clinical data for the 57-57 project,at the 8th World Congress on Inflammation

LUND, Sweden, June 18, 2007-Active Biotech (OMX Nordic: ACTI) has presented pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation (www.inflammation2007.dk) held in Copenhagen June 16-20*.

"The results strengthen the further clinical development of 57-57 for the treatment of SLE and show the possibility to reduce the use of steroids. Phase II clinical trials are planned to be initiated before year end", commented Sven Andréasson, President & CEO Active Biotech.

The new pre-clinical data presented show that 57-57, in an experimental model of the disease systemic lupus erythematosus (SLE), can replace prednisolone, an anti-inflammatory corticosteroid widely used in a broad range of different inflammatory diseases, among them SLE.

Several symptoms commonly associated with SLE, such as hematuria (blood in the urine) and glomerulonephritis (inflammation in the kidneys) could be significantly reduced when combining 57-57 and a lower dose of steroid.

Lund, June 18, 2007

Active Biotech AB (Publ)

Sven Andréasson President & CEO

About SLE and 57-57 Systematic Lupus Erythematosus (SLE) is a disease of the connective tissues that can cause inflammation and damage to the connective tissue in many different organs. The disease, which progresses in "flare-ups" interspersed with relatively symptom-free periods, primarily affects women of child-bearing age. Progress and symptoms of the disease vary widely, depending on the organs affected. Without treatment, SLE can be life-threatening. Active Biotech has decided to estimate the market conservatively at 1,000,000 patients in the US and Europe. The market potential for the SLE indication is estimated at approximately USD 6 billion.

The clinical program for the 57-57 project with the main indication SLE is proceedi
'"/>




Page: 1 2

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Gentiums Defibrotide Seen as Active in Multiple Myeloma
3. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
4. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
5. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
6. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
10. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
11. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
Post Your Comments:
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... a new market research report is available in its ... Market Report: 2010 Edition http://www.reportlinker.com/p0304775/Global-In-Vitro-Diagnostics-IVD-Market-Report-2010-Edition.html ... been experiencing rapid growth, in spite of the economic ... prevention of diseases among the people, which is expected ...
... today announced that industry veteran Glenn Kazo has assumed the ... capacities with Prolong since 2007. He succeeds Prolong founder Dr. ... have known Glenn for more than thirty years," said Dr. ... "I feel he is one of the greatest strategic minds ...
Cached Medicine Technology:Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 2Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 3Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 4Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 5Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President 2
(Date:12/22/2014)... (PRWEB) December 22, 2014 Sagacious Consultants, ... add a subscription option to their ad hoc report ... writing services. Customers can sign up for an annual ... hours each month at a deeply discounted hourly rate. ... and each has a progressively discounted rate. Subscription hours ...
(Date:12/22/2014)... Dec. 19, 2014 (HealthDay News) -- U.S. and state ... caramel apples that has killed at least four people ... should not eat any commercially produced, prepackaged caramel apples ... Disease Control and Prevention said in a news release. ... people had been infected with the outbreak strains of ...
(Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... Christmas is days away, and last minute ... easy solution that will please: the Sublime Gift Card ... from $25 up to $350," says Kathy Heshelow, founder of ... a wide array of skin care products and Skin Brushes." ... dates. , Gift delivery past shipping deadlines, or those ...
Breaking Medicine News(10 mins):Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... Calif., July 8 ChemoCentryx, Inc. today announced ... Officer, will give a keynote lecture at The 9th World ... "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and ... given on Thursday, July 9, 2009 at 9:00 am local ...
... Save Roughly $3,000 A Year By Switching From Expensive Brand ... Hyperactivity Disorder (ADHD) , , YONKERS, N.Y., July 8 ... Buy Drugs report, parents should be skeptical if their doctors ... of attention deficit hyperactivity disorder (ADHD). Free samples can ...
... Switzerland, 8 July 2009 - The International Diabetes Federation ... World Heart Federation (WHF) called today on the UN,s ... to avert the fastest growing threat by non-communicable diseases ... cardiovascular disease, diabetes, cancer and chronic respiratory disease, cause ...
... BETHEL, Conn., July 8 MedClean Technologies, Inc. (OTC Bulletin ... to exchange all of the Company,s existing Common Stock Purchase ... August 29, 2008 ("Existing Warrants") for newly issued Common Stock ... per share, exercisable for one-half the original number of shares ...
... July 8 Universal Health Services, Inc. (NYSE: UHS ... its Board of Directors. He becomes the eighth member of the ... of Hayground Cove Capital Partners LLC, in New York, NY, a ... that, Mr. Silvers was a Vice President at Fortress Investment Group ...
... , , , HARRISBURG, Pa., July 8 ... his office, the departments of Health and Education, and the ... H1N1 Influenza Preparedness Summit in Maryland on July 9. , ... information that will be used in Pennsylvania,s ongoing efforts to ...
Cached Medicine News:Health News:ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan 2Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 2Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 3Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 4Health News:The next health tsunami: Noncommunicable diseases 2Health News:MedClean Technologies Announces Results of Private Exchange Offer 2Health News:Rendell Administration Officials to Participate in National Flu Summit 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: